原发性肝癌类器官研究进展  

Advances in organoids of liver cancer

作　　者：孙乐毅 段斌炜[1] Sun Yueyi;Duan Binwei(Department of General Surgery Center,Beijing YouAn Hospital,Capital Medical University,Beijing Institute of Hepatology,Clinical Center for Liver Cancer,Capital Medical University,Beijing 100069,China)

机构地区：[1]首都医科大学附属北京佑安医院普通外科中心、北京肝病研究所、首都医科大学肝癌临床诊疗及研究中心,北京100069

出　　处：《中华肝胆外科杂志》2024年第7期549-552,共4页Chinese Journal of Hepatobiliary Surgery

基　　金：北京市自然科学基金(7222096);北京市自然科学基金-海淀原始创新联合基金(L222067);首都医科大学附属北京佑安医院中青年人才培养计划专项(YARCKB2022004、YARCKB2022005)。

摘　　要：原发性肝癌类器官技术为肝癌研究提供了新的体外模型,能够模拟肝癌的组织结构和遗传特征,适用于药物筛选和疾病机制研究。尽管存在培养成功率低和模拟微环境不足等,肝癌类器官的发展为个性化医疗和精准治疗提供了可能,有望成为肝癌治疗研究的关键工具。本文就原发性肝癌类器官的构建及其在药物筛选、肝癌发病机制研究中的应用进行综述。Organoid technology for primary liver cancer presents a novel in vitro model that faithfully reproduces the tissue architecture and genetic characteristics of liver cancer,serving as a platform for drug efficacy testing and disease mechanism exploration.Despite hurdles such as modest cultivation success rates and the challenge of fully mimicking the tumor microenvironment,the progression of liver cancer organoid technology holds the potential for advancing personalized medicine and tailored therapies,positioning it as a critical instrument in the investigation of liver cancer treatment strategies.This review delineates the techniques for construction methods of liver cancer organoids,their applications,and the existing constraints.

关 键 词：肝肿瘤 类器官 药物筛选试验 

分 类 号：R735.7[医药卫生—肿瘤]